GBGiorgio Maria Bressan

Giorgio Maria Bressan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Giorgio Maria Bressan has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Dino Volpin

    5 shared publications
  • Paola Braghetta

    Department of Molecular Medicine, University of Padova, Padova, Italy

    3 shared publications
  • Alfonso Colombatti

    Divisione di Oncologia Sperimentale, Centro di Riferimento Oncologico CRO-IRCCS, 33081 Aviano, Italy

    2 shared publications
  • Davide Girotto

    Department of Histology, Microbiology and Medical Biotechnologies, University of Padova, Padua 35121, Italy

    2 shared publications
  • Miriam Zanetti

    Department of Histology Microbiology and Medical Biotechnologies, University of Padua, 35100 Padua,1 Istituto per i Trapianti d'Organo e l'Immunocitologia, CNR,2 Unità Neuromuscolare, Istituti Ortopedici Rizzoli, 40136 Bologna,3 Divisione di Oncologia Sperimentale, CRO-IRCCS, 33081 Aviano, Italy4

    2 shared publications
  • Paolo Bonaldo

    Department of Histology Microbiology and Medical Biotechnologies, University of Padua, 35100 Padua,1 Istituto per i Trapianti d'Organo e l'Immunocitologia, CNR,2 Unità Neuromuscolare, Istituti Ortopedici Rizzoli, 40136 Bologna,3 Divisione di Oncologia Sperimentale, CRO-IRCCS, 33081 Aviano, Italy4

    2 shared publications

Latest Publications

  • Vascular Smooth Muscle Emilin-1 Is a Regulator of Arteriolar Myogenic Response and Blood Pressure

    by Gaia Litteri, Daniela Carnevale, Alessandra D’uRso, Giuseppe Cifelli, Paola Braghetta, Antonio Damato, Dario Bizzotto, Alessandro Landolfi, Francesco Da Ros, Patrizia Sabatelli, et al.

    Objective—: Emilin-1 is a protein of elastic extracellular matrix involved in blood pressure (BP) control by negatively affecting transforming growth factor (TGF)-β processing. Emilin1 null mice are hypertensive. This study investigates how Emilin-1 deals with vascular mechanisms regulating BP. Methods and Results—: This study uses a phenotype rescue approach in which Emilin-1 is expressed in either endothelial cells or vascular smooth muscle cells of transgenic animals with the Emilin1 −/− background. We found that normalization of BP required Emilin-1 expression in smooth muscle cells, whereas expression of the protein in endothelial cells did not modify the hypertensive phenotype of Emilin1 −/− mice. We also explored the effect of treatment with anti-TGF-β antibodies on the hypertensive phenotype of Emilin1 −/− mice, finding that neutralization of TGF-β in Emilin1 null mice normalized BP quite rapidly (2 weeks). Finally, we evaluated the vasoconstriction response of resistance arteries to perfusion pressure and neurohumoral agents in different transgenic mouse lines. Interestingly, we found that the hypertensive phenotype was coupled with an increased arteriolar myogenic response to perfusion pressure, while the vasoconstriction induced by neurohumoral agents remained unaffected. We further elucidate that, as for the hypertensive phenotype, the increased myogenic response was attributable to increased TGF-β activity. Conclusion—: Our findings clarify that Emilin-1 produced by vascular smooth muscle cells acts as a main regulator of resting BP levels by controlling the myogenic response in resistance arteries through TGF-β.


  • Open Access

    EMILIN-1 Deficiency Induces Elastogenesis and Vascular Cell Defects

    by Miriam Zanetti, Paola Braghetta, Patrizia Sabatelli, Isabella Mura, Roberto Doliana, Alfonso Colombatti, Dino Volpin, Paolo Bonaldo, Giorgio M. Bressan

    EMILINs constitute a family of genes of the extracellular matrix with high structural similarity. Four genes have been identified so far in human and mouse. To gain insight into the function of this gene family, EMILIN-1 has been inactivated in the mouse by gene targeting. The homozygous animals were fertile and did not show obvious abnormalities. However, histological and ultrastructural examination revealed alterations of elastic fibers in aorta and skin. Formation of elastic fibers by mutant embryonic fibroblasts in culture was also abnormal. Additional alterations were observed in cell morphology and anchorage of endothelial and smooth muscle cells to elastic lamellae. Considering that EMILIN-1 is adhesive for cells and that the protein binds to elastin and fibulin-5, EMILIN-1 may regulate elastogenesis and vascular cell maintenance by stabilizing molecular interactions between elastic fiber components and by endowing elastic fibers with specific cell adhesion properties.


  • SREBP contributes to induction of collagen VI transcription by serum starvation

    by Alessandra Ferrari, Silvia Maretto, Davide Girotto, Dino Volpin, Giorgio M Bressan


  • Open Access

    Collagen VI deficiency induces early onset myopathy in the mouse: an animal model for Bethlem myopathy

    by Paolo Bonaldo, Paola Braghetta, Miriam Zanetti, Stefano Piccolo, Dino Volpin, Giorgio M. Bressan

    To gain insight into the function of type VI collagen, the col6a1 gene was inactivated by targeted gene disruption in the mouse. The homozygous mutants lacked collagen VI in the tissues and showed histological features of myopathy such as fiber necrosis and phagocytosis and a pronounced variation in the fiber diameter. Muscles also showed signs of stimulated regeneration of fibers. Necrotic fibers were particularly frequent in the diaphragm at all ages examined. Similar, although milder, alterations were detected in heterozygous mutant mice, indicating haploinsufficiency of the col6a1 gene function. The data led us to conclude that collagen VI is necessary for maintenance of the integrity of muscle fibers and that the col6a1-deficient mouse can be considered an animal model of Bethlem myopathy.


  • Open Access

    Tissue‐Specific Expression of Promoter Regions of the αr1(VI) Collagen Gene in Cell Cultures and Transgenic Mice

    by Paola Braghetta, Paola Vitale, Stefano Piccolo, Paolo Bonaldo, Carla Fabbro, Davide Girotto, Dino Volpin, Giorgio Maria Bressan

    Cis-acting regions regulating transcription of the α1(VI) collagen chain have been investigated in vitro by transfection of promoter-CAT (where CAT is chloramphenicol acetyltransferase) constructs in different types of cultured cells and in vivo in transgenic mice carrying the same CAT constructs or minigenes derived from the fusion of genomic and cDNA sequences in which small deletions of the collagenous domain had been engineered. 215 bp of 5′-flanking sequence showed promoter activity in vitro, yet were not expressed in any tissue of six transgenic lines, indicating that this fragment contains the basal promoter, but not activator sequences. Constructs with 0.6 and 1.4kb of the 5′-flanking region produced significantly higher CAT activity in transfected cells and were expressed in tissues of about 30% of transgenic lines. Although CAT activity was totally unrelated to the pattern of expression of the α1(VI) mRNA, these results suggest the presence of an activator(s) between −0.2 and −0.6 kb from the transcription start site. When the promoter size was increased to 5.4 or 6.5 kb, CAT activity was stimulated several fold relative to the construct p1.4CAT and p4.0CAT in NIH3T3 fibroblasts and chick embryo chondroblasts. This stimulation was, however, not observed in C2C12 myoblasts. Transgenic mice generated with 6.SCAT construct or minigenes, containing 6.2 kb of promoter, exhibited very high levels of expression, which was similar to the relative amount α 1 (VI) mRNA in the majority of tissues, with the exception of lung, adrenal gland and uterus. CAT activity in tissues was 100–1000-fold higher than that measured in transgenic mice with shorter promoter (0.6 or 1.4kb). Since expression of minigenes was determined by RNase protection assay, the levels of mRNA per transgene copy were compared to those of the chromosomal gene and found to be always less than one quarter. These data suggest that the region -4.0/-5.4 contains an important activator(s) sequence which induces transcription in several, but not all, type VI collagen-producing tissues. Finally, analysis with the longest promoter fragment (7.5 kb) revealed a complex effect of the region -6.5/-7.5 on α1(VI) chain transcription. The sequence was inhibitory in NIH3T3 cells, indifferent in myoblasts and activating in chondroblasts in vitro, whereas transgenic animals generated with 7.5CAT construct produced a pattern of expression comparable to that of 6.5CAT and minigenes. During postnatal development transcription from both the endogenous gene and the transgenes decreased. However, the ratio of transgene/chromosomal gene expression was not constant, but varied in a way dependent on the tissue. This observation suggests that the fragment studied contains key sequences for the age-dependent regulation of the α1(VI) gene. No phenotypic alterations were induced by the presence of mutations in the minigenes.